[{"data":1,"prerenderedAt":252},["ShallowReactive",2],{"drug-carvedilol":3},{"id":4,"schemaVersion":5,"name":6,"category":9,"class":10,"brands":13,"synonyms":17,"formulations":20,"regimens":59,"contraindications":138,"warnings":148,"renal":149,"monitoring":150,"interactions":151,"review":152,"examples":155,"atc":169,"iran":171,"links":195,"populations":212,"usApproval":247},"carvedilol",1,{"fa":7,"en":8},"کارودیلول","Carvedilol","cardiovascular",{"fa":11,"en":12},"بتابلاکر غیرانتخابی با اثر آلفا","Non-selective beta-blocker with alpha-1 blockade",[14],{"name":15,"market":16},"Coreg","US",[18,7,19],"coreg","کارودیلل",[21,35,43,51],{"id":22,"form":23,"route":24,"label":25,"concentration":26,"markets":30,"refs":31},"tab-3-125","tablet","oral","3.125 mg tablet",{"amount":27,"unit":28,"perUnit":23,"scored":29},3.125,"mg",false,[16],[32],{"source":33,"section":34},"fda-carvedilol","3",{"id":36,"form":23,"route":24,"label":37,"concentration":38,"markets":40,"refs":41},"tab-6-25","6.25 mg tablet",{"amount":39,"unit":28,"perUnit":23,"scored":29},6.25,[16],[42],{"source":33,"section":34},{"id":44,"form":23,"route":24,"label":45,"concentration":46,"markets":48,"refs":49},"tab-12-5","12.5 mg tablet",{"amount":47,"unit":28,"perUnit":23,"scored":29},12.5,[16],[50],{"source":33,"section":34},{"id":52,"form":23,"route":24,"label":53,"concentration":54,"markets":56,"refs":57},"tab-25","25 mg tablet",{"amount":55,"unit":28,"perUnit":23,"scored":29},25,[16],[58],{"source":33,"section":34},[60,85,104,123],{"id":61,"disease":62,"label":63,"population":66,"type":70,"unit":28,"dose":71,"refs":73,"notes":76},"hf","heart-failure",{"fa":64,"en":65},"نارسایی قلبی — شروع ۳٫۱۲۵ mg دو بار در روز به مدت ۲ هفته","Heart failure — start 3.125 mg twice daily for 2 weeks",{"minAge":67},{"value":68,"unit":69},18,"year","fixed",{"perDose":27,"dosesPerDay":72},2,[74],{"source":33,"section":75},"2.1",[77],{"text":78,"refs":81},{"fa":79,"en":80},"در صورت تحمل به ۶٫۲۵، ۱۲٫۵ و ۲۵ mg دو بار، هر مرحله ≥۲ هفته. حداکثر ۵۰ mg دو بار در بیماران بالای ۸۵ kg با نارسایی خفیف تا متوسط. با غذا.","If tolerated, increase to 6.25, 12.5 and 25 mg twice daily, each step ≥2 weeks. Max 50 mg twice daily in patients >85 kg with mild–moderate HF. With food.",[82,83],{"source":33,"section":75},{"source":33,"section":84},"2",{"id":86,"disease":87,"label":88,"population":91,"type":70,"unit":28,"dose":93,"refs":94,"notes":97},"post-mi","acute-coronary-syndrome",{"fa":89,"en":90},"اختلال عملکرد بطن چپ پس از MI — شروع ۶٫۲۵ mg دو بار","LV dysfunction after MI — start 6.25 mg twice daily",{"minAge":92},{"value":68,"unit":69},{"perDose":39,"dosesPerDay":72},[95],{"source":33,"section":96},"2.2",[98],{"text":99,"refs":102},{"fa":100,"en":101},"افزایش به ۱۲٫۵ و سپس ۲۵ mg دو بار با فاصله ۳ تا ۱۰ روز.","Increase to 12.5 then 25 mg twice daily at 3–10 day intervals.",[103],{"source":33,"section":84},{"id":105,"disease":106,"label":107,"population":110,"type":70,"unit":28,"dose":112,"refs":113,"notes":116},"htn","hypertension",{"fa":108,"en":109},"فشار خون — شروع ۶٫۲۵ mg دو بار در روز","Hypertension — start 6.25 mg twice daily",{"minAge":111},{"value":68,"unit":69},{"perDose":39,"dosesPerDay":72},[114],{"source":33,"section":115},"2.3",[117],{"text":118,"refs":121},{"fa":119,"en":120},"پس از ۷ تا ۱۴ روز در صورت نیاز ۱۲٫۵ و سپس ۲۵ mg دو بار.","After 7–14 days if needed 12.5 then 25 mg twice daily.",[122],{"source":33,"section":115},{"id":124,"disease":62,"label":125,"population":128,"type":130,"unit":28,"dose":131,"refs":135},"peds",{"fa":126,"en":127},"زیر ۱۸ سال","Under 18 years",{"maxAge":129},{"value":68,"unit":69},"notCalculated",{"reason":132},{"fa":133,"en":134},"بی‌خطری و اثربخشی در کودکان ثابت نشده است.","Safety and effectiveness in pediatric patients not established.",[136],{"source":33,"section":137},"8.4",[139],{"id":140,"severity":141,"text":142,"refs":145},"asthma","block",{"fa":143,"en":144},"آسم برونشیال یا بیماری‌های برونکواسپاستیک (و سایر موارد بخش ۴).","Bronchial asthma or related bronchospastic conditions (and other items in section 4).",[146],{"source":33,"section":147},"4",[],[],[],[],{"status":153,"reviewer":154,"date":154},"unverified",null,[156,161,166],{"regimen":61,"formulation":22,"input":157,"expect":160},{"ageYears":158,"weightKg":159},60,75,{"perDose":27,"tabletsPerDoseRounded":5},{"regimen":105,"formulation":36,"input":162,"expect":165},{"ageYears":163,"weightKg":164},50,80,{"perDay":47},{"regimen":86,"formulation":36,"input":167,"expect":168},{"ageYears":158,"weightKg":164},{"perDose":39},[170],"C07AG02",{"status":172,"forms":173,"refs":190},"registered",[174,178,182,186],{"code":175,"en":176,"fa":177},"01924","CARVEDILOL 12.5MG TAB","قرص کارودیلول ۱۲٫۵ میلی‌گرم",{"code":179,"en":180,"fa":181},"01925","CARVEDILOL 25MG TAB","قرص کارودیلول ۲۵ میلی‌گرم",{"code":183,"en":184,"fa":185},"07448","CARVEDILOL 3.125MG TAB","قرص کارودیلول ۳٫۱۲۵ میلی‌گرم",{"code":187,"en":188,"fa":189},"02475","CARVEDILOL 6.25MG TAB","قرص کارودیلول ۶٫۲۵ میلی‌گرم",[191],{"source":192,"section":193,"url":194},"darooyab-generic","G-1586\u002FCarvedilol","https:\u002F\u002Fwww.darooyab.ir\u002FG-1586\u002FCarvedilol",[196,200,204,207,210],{"kind":197,"url":198,"label":199},"fda","https:\u002F\u002Fwww.accessdata.fda.gov\u002Fscripts\u002Fcder\u002Fdaf\u002Findex.cfm?event=overview.process&ApplNo=077614","ANDA077614",{"kind":201,"url":202,"label":203},"dailymed","https:\u002F\u002Fdailymed.nlm.nih.gov\u002Fdailymed\u002FdrugInfo.cfm?setid=ab8aa773-0ed1-4d59-a1bb-f46cf882644f","FDA Carvedilol",{"kind":205,"url":206,"label":8},"medlineplus","https:\u002F\u002Fmedlineplus.gov\u002Fdruginfo\u002Fmeds\u002Fa697042.html",{"kind":208,"url":209,"label":170},"who-atc","https:\u002F\u002Fatcddd.fhi.no\u002Fatc_ddd_index\u002F?code=C07AG02",{"kind":211,"url":194,"label":8},"darooyab",{"pregnancy":213,"lactation":222,"pediatric":230,"geriatric":238},{"level":214,"text":215,"quote":218,"refs":219},"caution",{"fa":216,"en":217},"برچسب خطر مشخصی برای بارداری ذکر نکرده یا داده کافی ندارد؛ فقط در صورت لزوم و با نظر پزشک.","Label states no clear risk or has limited data; use only if needed, under medical advice.","Risk Summary Available data regarding use of carvedilol in pregnant women are insufficient to determine whether there are drug-associated risks of adverse developmental outcomes.",[220],{"source":33,"section":221},"8.1",{"level":214,"text":223,"quote":226,"refs":227},{"fa":224,"en":225},"برچسب: در شیردهی با احتیاط؛ متن برچسب را ببینید.","Label: use with caution while breastfeeding; see the label text.","Risk Summary There are no data on the presence of carvedilol in human milk, the effects on the breastfed infant, or the effects on milk production.",[228],{"source":33,"section":229},"8.2",{"level":231,"text":232,"quote":235,"refs":236},"not-established",{"fa":233,"en":234},"برچسب: ایمنی و اثربخشی در کودکان ثابت نشده است.","Label: safety and effectiveness in children have not been established.","Effectiveness of carvedilol tablets in patients younger than 18 years has not been established.",[237],{"source":33,"section":137},{"level":239,"text":240,"quote":243,"refs":244},"ok",{"fa":241,"en":242},"برچسب: در سالمندان تفاوت یا تنظیم دوز خاصی ذکر نشده.","Label: no specific difference or dose adjustment stated for older adults.","With the exception of dizziness in hypertensive subjects (incidence 8.8% in the elderly versus 6% in younger subjects), no overall differences in the safety or effectiveness (see Figure 2 and 4) were observed between the older subjects and younger subjects in each of these populations.",[245],{"source":33,"section":246},"8.5",{"kind":248,"refs":249,"id":199},"ANDA",[250],{"source":33,"section":251},"SPL approval \u002F marketing category",1792191868657]